FDA close out note lifts Claris in India
This article was originally published in Scrip
Executive Summary
Shares of Claris Lifesciences surged on the Bombay Stock Exchange (BSE) after the company drew attention to a close out letter from US FDA, suggesting that the Indian firm may have successfully addressed concerns over deficiencies in current good manufacturing practices (cGMP) at its facility in Ahmedabad.